| Trial ID: | L4702 |
| Source ID: | NCT01740921
|
| Associated Drug: |
Liraglutide
|
| Title: |
GLP-1 and Microvascular Function in Type 2 Diabetes
|
| Acronym: |
GLP-1ADDS
|
| Status: |
COMPLETED
|
| Study Results: |
NO
|
| Results: |
|
| Conditions: |
Type 2 Diabetes
|
| Interventions: |
DRUG: Liraglutide|OTHER: diet|DRUG: Aspirin
|
| Outcome Measures: |
Primary: change of baseline skin maximum hyperaemia at 4 months, laser doppler fluximetry, baseline and 4 months | Secondary: change of baseline peripheral arterial tone at 4 months, ITAMAR, baseline and 4 months|change of baseline endothelial-dependent vasodilation at 4 months, iontophoresis, baseline and 4 months|change of baseline capillary density at 4 months, capillaroscopy, baseline and 4 months | Other: change of baseline clot structure at 4 months, rigidity and elasticity of clot structure, baseline and 4 months|change of baseline adipose tissue inflammation at 4 months, adipose tissue biopsies will be analysed for gene expression and protein content of inflammatory cytokines, baseline and 4 months
|
| Sponsor/Collaborators: |
Sponsor: Royal Devon and Exeter NHS Foundation Trust | Collaborators: University of Exeter
|
| Gender: |
ALL
|
| Age: |
ADULT, OLDER_ADULT
|
| Phases: |
|
| Enrollment: |
39
|
| Study Type: |
INTERVENTIONAL
|
| Study Designs: |
Allocation: RANDOMIZED|Intervention Model: PARALLEL|Masking: NONE|Primary Purpose: BASIC_SCIENCE
|
| Start Date: |
2011-01
|
| Completion Date: |
2016-02
|
| Results First Posted: |
|
| Last Update Posted: |
2017-02-17
|
| Locations: |
Peninsula Clinical Research Facility, Exeter, EX2 5DW, United Kingdom
|
| URL: |
https://clinicaltrials.gov/show/NCT01740921
|
